Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy.
Wenjia ChenJ Mark FitzGeraldTrung N TranRuth B MurrayChong Boon Nigel WongNasloon AliCono AritiEsther Garcia GilAnthony NewellMarianna AlacquaMona Al AhmadAlan AltrajaRiyad Al-LehebiMohit BhutaniBjermer LeifAnne Sofie BjerrumArnaud BourdinLakmini BulathsinhalaAnna von BülowJohn BusbyGiorgio Walter CanonicaVictoria CarterGeorge C ChristoffBorja García CosioRichard W CostelloJ Mark FitzGeraldJoão A FonsecaKwang Ha YooLiam G HeaneyEnrico HefflerMark HewOle HilbergFlavia HoyteTakashi IwanagaDavid J JacksonRupert C JonesMariko Siyue KohPiotr KunaDésirée Erlinda Larenas-LinnemannSverre LehmannLauri A LehtimäkiJuntao LyuBassam MahboubJorge MasperoAndrew N Menzies-GowConcetta SirenaPapadopoulos G NikolaosAndriana I PapaioannouLuis A Perez-de-LlanoDiahn-Warng PerngMatthew PetersPaul E PfefferCeleste M PorsbjergTodor A PopovChin Kook RheeSundeep SalviCamille TailléChristian TaubeCarlos Arturo Torres-DuqueCharlotte Suppli UlrikSeung Won RaEileen WangMichael E WechslerDavid J PricePublished in: Journal of asthma and allergy (2022)
Around one third of severe HOCS asthma patients did not receive biologics despite a similar high burden of asthma exacerbations as those who initiated a biologic therapy. Other disease characteristics such as eosinophilic phenotype, serious infectious events, nasal polyps, airflow limitation and lack of asthma control appear to dictate biologic use.